BMS-754807 is primarily used in research settings as a potent and selective inhibitor of insulin-like growth factor 1 receptor (IGF-1R) and insulin receptor (IR). It has shown potential in preclinical studies for targeting cancer cells, particularly those that rely on IGF-1R signaling pathways for growth and survival. Researchers are exploring its efficacy in inhibiting tumor progression in various cancers, including breast, prostate, and lung cancer. Additionally, it is being investigated for its role in combination therapies to enhance the effectiveness of other anticancer drugs. Its ability to modulate insulin signaling pathways also makes it a candidate for studying metabolic disorders and diabetes-related research.